News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
740,068 Results
Type
Article (41954)
Company Profile (203)
Press Release (697889)
Multimedia
Podcasts (110)
Webinars (15)
Section
Business (210115)
Career Advice (1940)
Deals (35213)
Drug Delivery (133)
Drug Development (79956)
Employer Resources (158)
FDA (16201)
Job Trends (15417)
News (349279)
Policy (33018)
Tag
2027 Biotech Bay Standard (1)
2027 Pharm Country Standard (1)
Academia (2772)
Accelerated approval (43)
Adcomms (28)
Allergies (174)
Alliances (46417)
ALS (203)
Alzheimer's disease (1821)
Antibody-drug conjugate (ADC) (404)
Approvals (16520)
Artificial intelligence (659)
Autoimmune disease (244)
Automation (52)
Bankruptcy (333)
Best Places to Work (12325)
BIOSECURE Act (23)
Biosimilars (216)
Biotechnology (143)
Bladder cancer (185)
Brain cancer (70)
Breast cancer (720)
Cancer (5586)
Cardiovascular disease (497)
Career advice (1588)
Career pathing (27)
CAR-T (317)
CDC (47)
Celiac Disease (1)
Cell therapy (873)
Cervical cancer (43)
Clinical research (69129)
Collaboration (2054)
Company closure (5)
Compensation (1295)
Complete response letters (83)
COVID-19 (2533)
CRISPR (106)
C-suite (1039)
Cystic fibrosis (155)
Data (7215)
Decentralized trials (3)
Denatured (26)
Depression (172)
Dermatology (59)
Diabetes (578)
Diagnostics (7287)
Digital health (54)
Diversity (7)
Diversity, equity & inclusion (40)
Drug discovery (328)
Drug pricing (190)
Drug shortages (31)
Duchenne muscular dystrophy (276)
Earnings (100358)
Editorial (61)
Employer branding (21)
Employer resources (126)
Events (130719)
Executive appointments (1104)
FDA (19741)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (29)
Funding (1707)
Gene editing (228)
Generative AI (60)
Gene therapy (710)
GLP-1 (1117)
Government (5072)
Grass and pollen (8)
Guidances (400)
Healthcare (20733)
HIV (77)
Huntington's disease (55)
IgA nephropathy (96)
Immunology and inflammation (317)
Immuno-oncology (86)
Indications (156)
Infectious disease (2872)
Inflammatory bowel disease (220)
Inflation Reduction Act (14)
Influenza (137)
Intellectual property (279)
Interviews (328)
IPO (17223)
IRA (52)
Job creations (3432)
Job search strategy (1379)
JPM (66)
Kidney cancer (19)
Labor market (98)
Layoffs (617)
Leadership (22)
Legal (7748)
Liver cancer (104)
Longevity (27)
Lung cancer (747)
Lymphoma (415)
Machine learning (51)
Management (44)
Manufacturing (954)
MASH (189)
Medical device (14881)
Medtech (14964)
Mergers & acquisitions (19228)
Metabolic disorders (1503)
mRNA (180)
Multiple sclerosis (182)
NASH (21)
Neurodegenerative disease (416)
Neuropsychiatric disorders (110)
Neuroscience (3310)
Neurotech (1)
NextGen: Class of 2026 (7105)
Non-profit (5066)
Now hiring (56)
Obesity (718)
Opinion (268)
Ovarian cancer (187)
Pain (243)
Pancreatic cancer (266)
Parkinson's disease (361)
Partnered (27)
Patents (571)
Patient recruitment (612)
Peanut (65)
People (58672)
Pharmaceutical (42)
Pharmacy benefit managers (31)
Phase 1 (21602)
Phase 2 (30589)
Phase 3 (22942)
Pipeline (7237)
Policy (286)
Postmarket research (2196)
Preclinical (9065)
Press Release (71)
Prostate cancer (290)
Psychedelics (55)
Radiopharmaceuticals (324)
Rare diseases (1062)
Real estate (5779)
Recruiting (61)
Regulatory (25252)
Reports (63)
Research institute (2534)
Resumes & cover letters (342)
Rett syndrome (32)
RNA editing (17)
RSV (94)
Schizophrenia (172)
Series A (290)
Series B (211)
Service/supplier (9)
Sickle cell disease (113)
Special edition (29)
Spinal muscular atrophy (174)
Sponsored (36)
Startups (3382)
State (2)
Stomach cancer (19)
Supply chain (121)
Tariffs (69)
The Weekly (82)
Vaccines (1069)
Venture capital (104)
Weight loss (475)
Women's health (106)
Worklife (15)
Date
Today (190)
Last 7 days (721)
Last 30 days (2982)
Last 365 days (32141)
2026 (8236)
2025 (32448)
2024 (37308)
2023 (42381)
2022 (53017)
2021 (57342)
2020 (56695)
2019 (50583)
2018 (37408)
2017 (33677)
2016 (33120)
2015 (38525)
2014 (31629)
2013 (26798)
2012 (28035)
2011 (28758)
2010 (25654)
Location
Africa (752)
Alabama (97)
Alaska (7)
Arizona (295)
Arkansas (15)
Asia (43902)
Australia (7184)
California (12559)
Canada (3573)
China (1307)
Colorado (539)
Connecticut (545)
Delaware (373)
Europe (98763)
Florida (1897)
Georgia (414)
Hawaii (3)
Idaho (64)
Illinois (1017)
India (84)
Indiana (586)
Iowa (22)
Japan (501)
Kansas (129)
Kentucky (48)
Louisiana (41)
Maine (85)
Maryland (1556)
Massachusetts (9171)
Michigan (375)
Minnesota (711)
Mississippi (7)
Missouri (151)
Montana (37)
Nebraska (29)
Nevada (142)
New Hampshire (89)
New Jersey (3409)
New Mexico (32)
New York (3334)
North Carolina (1683)
North Dakota (10)
Northern California (6203)
Ohio (388)
Oklahoma (25)
Oregon (45)
Pennsylvania (2519)
Puerto Rico (26)
Rhode Island (49)
South America (1142)
South Carolina (76)
South Dakota (1)
Southern California (4953)
Tennessee (202)
Texas (1988)
United States (45076)
Utah (380)
Vermont (1)
Virginia (311)
Washington D.C. (79)
Washington State (1029)
West Virginia (4)
Wisconsin (134)
Wyoming (2)
740,068 Results for "20".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
People
Gilead Chief Gets 20% Pay Bump, Still Falls Short of $30M Club
Gilead’s median employee compensation in 2025 was $238,979. Daniel O’Day’s compensation package is 119 times larger.
March 24, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Akeso Advances “IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab
March 25, 2026
·
6 min read
Press Releases
20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program
March 24, 2026
·
5 min read
Press Releases
20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies
March 12, 2026
·
7 min read
Press Releases
Connect Biopharma Announces $20.2 Million Private Placement Financing
March 30, 2026
·
5 min read
Press Releases
MediWound Files Annual Report on Form 20-F
March 5, 2026
·
1 min read
Press Releases
20/20 BioLabs Debuts Trading on Nasdaq Under Ticker Symbol “AIDX” Following 3 Consecutive Years of Sales Growth
February 19, 2026
·
6 min read
Press Releases
Qiagen Announces Form 20-F Annual Report Filing for 2025 Results
March 20, 2026
·
1 min read
Press Releases
Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock
March 19, 2026
·
7 min read
Obesity
Lilly’s Amylin Agonist Headed to Phase III After Eliciting up to 20% Weight Loss
The highest dose of Eli Lilly’s eloralintide led to 20.1% weight loss after 48 weeks in a Phase II trial, exceeding analyst expectations and highlighting a “potentially best in class profile,” according to BMO Capital Markets.
November 6, 2025
·
3 min read
·
Heather McKenzie
1 of 74,007
Next
